NEW YORK (360Dx) – Hennigsdorf, Germany-based Sphingotec said today that it recently signed an agreement with Mayo Clinic to collaborate on the evaluation and use of biomarkers that could improve the diagnosis of certain disease states, including kidney disease, breast cancer, sepsis, and cardiovascular disease.

Under the agreement, for research and potential routine clinical use, Mayo Clinic will evaluate proenkephalin (penKid), a blood-based biomarker that provides information on the current status of kidney function, and three other biomarkers, Sphingotec said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.